Clinical trial
A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
NCT00057564 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
- Lead sponsor
- Celgene Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2003
- Completion date
- August 31, 2013
- Enrollment
- 470 (actual)
- Sites
- 99
Conditions
As the registry lists them; a condition with its own page is linked.